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The endothelium plays a key role in vascular homeostasis
through the release of a variety of autocrine and paracrine
substances (1). In addition to vasodilation, a healthy endo-
thelium is antiatherogenic because of effects that include
inhibition of platelet aggregation and adhesion, smooth
muscle cell proliferation and leukocyte adhesion. Dysfunc-
tion of endothelial cells is a systemic process and the
initiating event in atherosclerosis, and is important in the
ischemic manifestations of the disease process as well.
Endothelial cell dysfunction occurs in the presence of
atherosclerosis or its risk factors, particularly hypercholes-
terolemia (2). Over the past five years, new methodology has
allowed more widespread assessment of endothelium-
dependent vasodilation in patients in a variety of research
settings. This review will focus on the assessment of
endothelial function in humans and the therapeutic options
that are now available for treating abnormalities in vascular
function.
ROLE OF THE ENDOTHELIUM IN HEALTH
Local vascular control depends on a balance between dila-
tors and constrictors, with endothelium-dependent nitric
oxide (NO) being the best characterized and probably the
most important (1,3). Nitric oxide is stimulated by a variety
of stimuli that serve as the basis for the assessment of
endothelium-dependent vasodilation (Table 1). The major
opposition to the vasodilator substances is endothelin, a
21-amino acid peptide and a potent vasoconstrictor. A local
renin-angiotensin system exists in several tissues, including
the vascular endothelium, heart and monocytes (4), and
angiotensin II, another vasoconstrictor, is very important in
local vascular control.
Vasomotion. In healthy people, the predominant effect of
stimulation of the endothelium is vasodilation. It is well
established in animals that basal release of NO exists in both
conduit and resistance vessels (5). This is true in the human
coronary circulation as well (6). Basal tone is probably also
mediated by endothelin (7), angiotensin II (8) and prosta-
cyclin (9). In the coronary circulation, endothelium-
dependent stimulation causes vasodilation of epicardial
vessels (10). Acetylcholine-induced vasodilation can be
blocked by NO synthase (NOS) inhibition with N-
monomethyl-L-arginine (L-NMMA) (6). Resistance vessel
function is determined in vivo by measuring blood flow.
Administration of endothelium-dependent agonists result
in an increase in blood flow in the human peripheral and
coronary circulations (11). Whereas this effect has also been
shown to be NO dependent (6), other mediators probably
are involved in resistance vessel dilation and the control of
coronary blood flow, particularly to metabolic stimuli
(12,13).
Leukocyte adhesion. Antiinflammatory properties of the
healthy endothelium are important in the prevention of
atherosclerosis and ischemic coronary syndromes (14). Mul-
tiple families of “adhesion molecules” provide trafficking
signals for the interaction between leukocytes and the
endothelium. A detailed description of the events of mono-
cyte adhesion is reviewed elsewhere (15). Leukocyte adhe-
sion is not only important during the early stages of
atherogenesis, but may contribute significantly to plaque
instability and rupture (16).
Atherosclerosis and its risk factors result in upregulation
of cell adhesion molecules by the nuclear factor-kb-
regulating gene expression through redox-sensitive mecha-
nisms (17). This pathway can be mediated by a number of
cytokines including interleukins, tumor necrosis factor-
alpha, monocyte chemotactic protein and interferon. Nitric
oxide has been shown to inhibit leukocyte adhesion (18).
Soluble forms of adhesion molecules can be measured in
blood and serve as markers of endothelial activation (19). It
was recently shown in the Physicians Health Study that
sICAM-1 (soluble intercellular adhesion molecule-1) was
predictive of future myocardial infarction (20).
Platelet function. Nitric oxide is antithrombotic via potent
antiaggregating and antiadhesive properties (21). Nitric
oxide inhibits expression of P-selectin on platelets and
suppresses the calcium-dependent conformational change in
the glycoprotein (GP) IIb-IIIa receptor required for fibrin-
ogen binding (22). Platelet activation occurs in conditions
associated with impairment of endothelium-dependent va-
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sodilation (23). Platelet function can be assessed by standard
aggregation techniques. More recently, flow cytometry has
been used to quantify the expression of P-selectin and GP
IIb/IIIa receptors, markers of platelet activation (24).
Platelet activation is particularly important in unstable
coronary syndromes and coronary intervention where block-
ade of the GP IIb/IIIa receptor is becoming a mainstay of
therapy (25). Because P-selectin is present on both platelets
and the endothelium, it plays an important role in the
interaction with platelets, leukocytes and the endothelium
(26). It was recently demonstrated that platelets from
patients with unstable coronary syndromes release less NO
(27). The release products of activated platelets mediate
vasoconstriction at sites of endothelial dysfunction (28).
Other functions of the healthy endothelium are shown in
Table 2.
ASSESSMENT OF
ENDOTHELIAL FUNCTION IN HUMANS
Intracoronary studies. Ludmer et al. (2) were among the
first to demonstrate that acetylcholine (up to 1026 M) could
be safely infused selectively into the coronary circulation to
assess conduit vessel vasomotion. This has served as the gold
standard for endothelial function testing for the last decade.
Acetylcholine-induced vasoconstriction is one of the earliest
manifestations of endothelial dysfunction (29), occurring
before abnormalities with other endothelium-dependent
stimuli (cold presor testing, flow-mediated vasodilation
[FMD]). L-NMMA can be selectively infused to assess
basal NO activity in the coronary circulation. Resistance
vessel function in the coronary circulation can now be
readily assessed by measuring coronary blood flow with
intracoronary Doppler wires (30). Coronary blood flow
increases in response to infused agonists, such as acetylcho-
line, and the magnitude of this increase can be used as a
quantitative measure of endothelial function. The change in
coronary blood flow is due to both the direct effect of the
infused agonist and the resulting FMD. When compared
with conduit vessel responses, the measurement of coronary
blood flow is somewhat more difficult with greater variabil-
ity and expense. Coronary blood flow has also been assessed
by coronary sinus thermodilution techniques in laboratories
equipped to do this.
Positron emission tomography. Quantitative assessment
of myocardial blood flow and metabolic activity can be made
by positron emission tomography scanning (31,32). Both
basal flow and hyperemic flow (usually to intravenous
dipyridamole) can be obtained to calculate coronary flow
reserve (33). Because the increase in myocardial flow is
related to adenosine-induced increases and flow-mediated
vasodilation, it is in part a measure of endothelial function.
This technique is noninvasive and has the advantage of the
potential for multiple tests per patient; however, it is very
expensive and limited to a small number of laboratories
(34,35).
Impedance plethysmography. Hokanson et al. (36) de-
scribed electrically calibrated plethysmography for direct
measurement of limb blood flow. The apparatus is relatively
inexpensive and versatile because direct intraarterial infu-
sions of methacholine or acetylcholine assess endothelial
function (37,38). Because forearm blood flow (ml/min/100
ml) is measured, venous occlusion plethysmography reflects
resistance vessel function in the forearm. Although ideally
suited for one-time measurements, there is some concern
about day-to-day variability, and as such, it has not been
extensively used for long-term intervention studies.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
EDHF 5 endothelium-derived hyperpolarizing
factor
FMD 5 flow-mediated vasodilation
GP 5 glycoprotein
LDL 5 low-density lipoprotein
L-NMMA 5 NG-monomethyl L-arginine
NO 5 nitric oxide
NOS 5 nitric oxide synthase
Table 1. Vasodilator Stimuli to Assess Endothelial Function
Acetylcholine Blood flow (shear stress)
Bradykinin Catecholamines
Serotonin A 23187
ADP, ATP Calcium gene-related peptide
Histamine Platelet-activating factor
Thrombin Substance P
ADP 5 adenosine diphosphate; ATP 5 adenosine triphosphate; A 23187 5 calcium
ionophore.
Table 2. Function of the Healthy Endothelium
Role Substances
Vasoregulation NO, EDHF, PGI2, ET-1,
Ang II, TXA2
Coagulation PGI2, TXA2, vWF, fibrinogen,
thrombomodulin, TF
Fibrinolysis t-PA, PAI-1
Inflammation P and E selectin, VCAMs and
ICAMs, NF-kb
Erythrocyte adherence Integrins
Permeability RAGE
Vasculogenesis/angiogenesis VEGF, PDGF, TGF-b
Ang II 5 angiotensin II; EDHF 5 endothelium-derived hyperpolarizing factor;
ET-1 5 endothelin-1; ICAM 5 intercellular adhesion molecule; NF-kb 5 nuclear
factor kappa beta; NO 5 nitric oxide; PAI-1 5 plasminogen activator inhibitor;
PDGF 5 platelet-derived growth factor; PGI2 5 prostacyclin; RAGE 5 receptor for
advanced glycosylated end-products; TF 5 tissue factor; TGF-b 5 transforming
growth factor-beta; t-PA 5 tissue plasminogen activator; TXA2 5 thromboxane;
VCAM 5 vascular cellular adhesion molecule; VEGF 5 vascular endothelial growth
factor; vWF 5 von Willebrand’s factor.
632 Anderson JACC Vol. 34, No. 3, 1999
Assessment of Endothelial Function September 1999:631–8
Brachial ultrasound. Celermajer et al. (39) were the first to
describe a noninvasive assessment of flow-mediated vasodi-
lation in the brachial or femoral artery. Upper-arm occlu-
sion for 5 min results in reactive hyperemia after the cuff is
released (blood flow increases five- to sevenfold), and this
increase in shear stress results in FMD (Fig. 1). The
variability is acceptable (about 2%), and the measurements
are reproducible in a good laboratory (40). Brachial artery
FMD has been shown to correlate with measures of
coronary endothelial function (41). The main advantages of
this approach are the noninvasive nature and the ability to
repeat multiple tests in the same patient or the study of large
numbers of patients. Some laboratories are now using direct
tracking ultrasound technology that may improve the pre-
cision of the technique (Drexler H, personal communica-
tion, 1998).
Venous studies. Dorsal hand vein compliance can be
assessed with the linear variable differential transducer
technique (42). This technique uses local infusions of
agonists into the hand veins with an assessment of conduit
vessel compliance. In terms of invasiveness and utility, it
would be similar to impedance plethysmography, except
that venous conduit vessels are studied instead of forearm
resistance arterial vessels.
ENDOTHELIAL DYSFUNCTION
The term endothelial dysfunction is most often used to
denote impairment of endothelium-dependent vasodilation,
but probably encompasses those conditions leading to en-
dothelial activation with abnormalities in endothelial inter-
actions with leukocytes, platelets and regulatory substances
(43–46) (Table 3).
Atherosclerosis. It is the general consensus of vascular
biologists that endothelial injury with resulting dysfunction
is the initiating event in atherosclerosis (47) and plays an
important role in the ischemic manifestations of coronary
disease. Ludmer et al. (2) were among the first to recognize
this in human coronary arteries. In health, acetylcholine
causes vasodilation as a result of endothelium-dependent
release of NO; in disease, the effect of NO is decreased, and
unopposed muscarinic smooth muscle cell activation leads to
vasoconstriction. Atherosclerosis also impairs acetylcholine-
induced increases in coronary blood flow, despite the fact
that resistance vessels are rarely affected by the physical
presence of atherosclerosis (11). Part of the dysfunction in
atherosclerosis is related to a decrease in NOS activity (48).
In balloon-injury models of atherosclerosis, there is
emerging evidence that angiotensin II blockade or ACE
inhibition decreases intimal proliferation; however, this has
not translated into a decrease in restenosis rates in studies of
angioplasty in humans. Depending on the animal model,
angiotensin II appears to be an important mediator of
intimal proliferation and vasomotion (49). Increased endo-
thelin activity also appears to play a role in endothelial
dysfunction in atherosclerosis (50).
Cardiovascular risk factors. Endothelial dysfunction, a
systemic disturbance of function, precedes the physical
presence of atherosclerosis (51,52). Oxidative stress appears
to play a pivotal role in the alteration of endothelial function
that characterizes all risk factors (Fig. 1). Steinberg and
others have advanced the concept that oxidative modifica-
tion of low-density lipoprotein (LDL) is central to the
development of atherosclerosis, and recent work has sug-
gested that oxidized LDL plays an important role in
abnormal endothelial vasorelaxation (53). The detrimental
effects of oxidized LDL on endothelial function are likely
modulated through lysophosphatidylcholine (54), protein
kinase C (55) and G proteins (56). In addition, oxygen-free
radicals impair endothelial function through direct inacti-
vation of NO (57). Oxidized LDL also increases the
production of endothelin in cultured cells and intact blood
vessels (58).
Tetrahydrobiopterin is a cofactor for NOS, the rate-
limiting enzyme responsible for the conversion of L-arginine
to NO. activation of NOS at suboptimal concentrations of
tetrahydrobiopterin leads to the production of hydrogen
peroxide instead of NO (59). Relative deficiency of tetra-
Figure 1. High-resolution ultrasound image of brachial artery at
baseline and 1 min after upper-arm occlusion cuff release and
subsequent flow-mediated vasodilation.
Table 3. Conditions Associated With Impaired Endothelium-
dependent Vasodilation
Atherosclerosis Type I and type II diabetes mellitus
Hypercholesterolemia Hyperglycemia
Low HDL cholesterol Acute postprandial
hypertriglyceridemia
High Lp(a) Active and passive cigarette
smoking
Small LDL particles Dilated cardiomyopathy
Susceptibility of LDL
to oxidation
Chagas disease
Hypertension Heart failure—any cause
Hyperhomocysteinemia Family history of coronary disease
Aging Postmenopausal status
Vasculitic conditions Post-Kawasaki’s disease
Transplantation
atherosclerosis
Pregnancy-induced hypertension/
preeclampsia
Syndrome X and
variant angina
Pulmonary hypertension
Insulin resistance Methionine loading
HDL 5 high-density lipoprotein; LDL 5 low-density lipoprotein.
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hydrobiopterin has been implied as contributing to endo-
thelial dysfunction in some conditions (60).
Hypercholesterolemia induces a number of changes on
vascular homeostasis, including a decrease in NO bioactiv-
ity, an increase in superoxide production, an increase in
endothelin immunoreactivity (61), an increase in adhesion
molecules (19) and attenuation of endothelium-dependent
vasodilation (37). The combination of diabetes and hyper-
tension appears to have an additive effect on monocyte
adhesion (62). It seems that cholesterol-induced endothelial
dysfunction is related to the degree of LDL oxidation and
not LDL concentration itself (63,64). Acute elevations of
free fatty acids and triglycerides can attenuate vasodilator
responses over the course of several hours (65,66). Acute
hyperglycemia (6 h) can also impair vasomotor responses
(67), adding evidence to the belief that it is the milieu of the
artery that determines vascular function, and this can be
modulated over minutes to hours.
Attenuation of endothelium-dependent responses is an
important manifestation in many other cardiac and noncar-
diac conditions. Detailed discussion is beyond the scope of
the current review (38,68–72) (see Table 3).
TREATMENT OF ENDOTHELIAL DYSFUNCTION
In the 1990s, studies have demonstrated that endothelial
dysfunction in both animal models and humans can be
attenuated by a variety of interventions (Table 4).
Cholesterol lowering. Ohara et al. (73) demonstrated that
cholesterol feeding increased the production of superoxide
from the endothelium of rabbit aorta, and that dietary
lowering of cholesterol not only improved endothelium-
dependent vasodilation, but also normalized endothelial
superoxide production (74). The finding that cholesterol
lowering was associated with an improvement in
endothelium-dependent vascular relaxation is in keeping
with prior animal studies (75).
We studied the effect of LDL lowering and the combi-
nation of LDL lowering and antioxidant therapy on coro-
nary epicardial endothelial function (76). Whereas LDL
lowering resulted in an improvement in endothelial func-
tion, the combination of lovastatin and probucol resulted in
near normalization in endothelial function. The acetylcho-
line response at follow-up, or the improvement in endothe-
lial response over the study period, was closely related to the
resistance of LDL oxidation (63). Whereas we treated
patients for one year, Tamai et al. (77) recently demon-
strated that forearm blood flow can be modulated within
hours after LDL pheresis, demonstrating the dynamic
nature of this process. Studies with other modalities to
lower cholesterol have shown improved function as well,
suggesting that it is the cholesterol-lowering effect and not
the pleiotrophic effect of the statins that are important
(31,78).
Antioxidants. Animal studies by Keaney et al. (79,80) have
demonstrated beneficial effects of probucol and antioxidant
vitamin therapy beyond protection of LDL. Recently,
studies have demonstrated that vitamin C acutely improves
endothelium-dependent responses in the forearm circula-
tion in patients with a variety of risk factors (81–84).
Long-term studies on vascular function in humans with
vitamin C have not been reported.
Although alpha-tocopherol has been shown to protect
LDL against oxidation in humans (85), longer-term studies
using antioxidant vitamins have not shown any effect on
endothelium-dependent vasodilation (86,87). Recently, two
weeks of vitamin E treatment was shown to decrease
P-selectin in patients with hypercholesterolemia, suggesting
attenuation of endothelial activation (19).
Angiotensin-converting enzyme (ACE) inhibition. An-
giotensin II has been shown to increase superoxide produc-
tion via membrane-bound NADH/NADPH (88). Al-
though it is unclear whether angiotensin II blockers result in
improved endothelial function, these data are available for
ACE inhibitors (8,89). The ACE inhibitors could poten-
tially improve endothelium-dependent vasodilator responses
through decreased levels of angiotensin II, increased levels
of bradykinin and NO.
In humans, acute administration of ACE inhibitors
augmented endothelium-dependent vasodilation in both
the coronary and peripheral circulation (90,91). Mancini et
al. (92) recently reported that the tissue-specific ACE
inhibitor quinapril attenuated coronary endothelial dysfunc-
tion in patients with coronary artery disease.
To assess the potential differences in tissue specificity
among ACE inhibitors (93) and the importance of the
bradykinin effect, we recently compared quinapril, enalapril,
losartan and amlodipine in a cross-over design in 80 patients
with coronary artery disease. Over an 8-week treatment
period, improvement in brachial artery FMD was only seen
in the quinapril group, suggesting potential differences
among vasoactive medications (94). Two recent studies
using enalapril or lisinopril reported negative results as well
Table 4. Treatment Associated With Improvement of
Endothelial Dysfunction in Humans
Acute Chronic
LDL lowering with pheresis LDL lowering with statins,
resins
ACE inhibition ACE inhibition
Antioxidants (Vitamin C and
E 1 C)
Antioxidants (probucol with
lovastatin)
Estrogen Estrogen
L-arginine, D-arginine Estrogen 1 progesterone
Tetrahydrobiopterin,
methyltetrahydrofolate
L-arginine
Deferoxamine Exercise
Glutathione
Calcium channel blockers
ACE 5 angiotensin-converting enzyme; LDL 5 low-density lipoprotein.
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(95,96). The effect of lowering blood pressure by other
means on endothelial function is less clear, but it appears
that ACE inhibitors have unique vascular protective prop-
erties.
Hormone replacement therapy. Hormone replacement
with estrogen has been shown to improve endothelium-
dependent vasorelaxation acutely in a number of animal
models, including primate coronary arteries (97). It is likely
that benefit is both NO dependent and independent (98).
Sack et al. (99) demonstrated that estrogen attenuates the
susceptibility of LDL to oxidation in women. Studies in
postmenopausal women demonstrated that acetylcholine-
induced coronary vasoconstriction (100,101), but not met-
abolic vasodilation (102), can be attenuated in as little as
10 min by either intracoronary or intravenous administra-
tion of estrogen. Guetta et al. have demonstrated that the
acute beneficial effects of estrogen on blood flow are NO
related because this can be attenuated with L-NMMA
(103). Improved endothelial vascular responses have been
demonstrated in the peripheral circulation after nine weeks
of estradiol therapy (104), and these effects were not
attenuated by the coadministration of progesterone (105).
Medroxyprogesterone, which is commonly used in combi-
nation with estrogen, probably has a detrimental effect on
endothelial responses (106). Long-term studies evaluating
the effect of hormone replacement on coronary
endothelium-dependent vasodilation are underway.
Other interventions. Augmentation of NO production by
L-arginine supplementation has been shown to improve
vascular relaxation acutely in certain conditions (107). A
recent study demonstrated improved brachial artery FMD
in hypercholesterolemic subjects after four weeks of oral
L-arginine supplementation (108). It is interesting to note
that Quyyumi (109) more recently demonstrated augmen-
tation of Ach-induced changes in forearm blood flow
acutely with both L- and D-arginine, suggesting other
mechanisms of action of arginine.
A variety of other interventions that have been shown to
modulate vasomotor responses in humans are shown in
Table 4. Most of these were administered acutely, and
further studies are required to assess their long-term use.
PERSPECTIVE
The clinical manifestations of coronary disease depend on a
multitude of interrelated pathophysiologic processes, of
which endothelial dysfunction is only one. A wealth of
indirect evidence argues that the endothelium plays a vital
role in atherosclerosis and its manifestations. Endothelial
dysfunction is generally believed to be the inciting event in
atherosclerosis (47), and is probably important in ischemic
manifestations as well. We demonstrated that endothelial
dysfunction was associated with the development of athero-
sclerosis as assessed by intravascular ultrasound in patients’
postcardiac transplantation (110). Those participants with
normal vasodilator responses to acetylcholine developed
atherosclerosis at a rate one-third that of those with endo-
thelial dysfunction. Studies of cholesterol lowering, antiox-
idant therapy and ACE inhibition also suggest that atten-
Figure 2. Oxidative stress leads to attenuation of endothelium-dependent vasodilation by: 1) decreased production of NO through
oxidized LDL-mediated mechanisms, and by 2) increased destruction of NO by superoxide. See text for details. Gi 5 pertussis sensitive
G protein; O2 5 superoxide anion; ONOO
2 5 peroxynitrite anion; PKC 5 protein kinase C; cNOS 5 constitutive form of nitric oxide
synthase; ET 5 endothelin; AT II 5 angiotensin II; ox-LDL 5 oxidized LDL; lyso PC 5 lysophosphatidylcholine; sGC 5 soluble
guanylate cyclase; cGMP 5 cyclic guanosine monophosphate; NFKB 5 nuclear factor kappa beta.
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uation of endothelial dysfunction provides the link between
basic scientific observations and the decrease in cardiac
events observed in the megatrials. However, it is not clear at
this stage whether this is causal and if improvement in
endothelium-dependent vasodilation is clinically relevant.
However, we are currently at a stage where the impor-
tance of measuring endothelial function in individual pa-
tients is unknown. The noninvasive technique is well suited
for group studies in laboratories that are expert in its
application and measurement (Fig. 2). Even in these labo-
ratories, the day-to-day variability is at least 20% to 25%
(just as it is with other measures of endothelial function). In
laboratories that have not done a lot of testing and do not
use careful off-line measurements, the variability will be at
least twice that. Thus, before we openly embrace endothelial
function testing, significantly more research has to be done.
Standard methodology needs to be established. Large pop-
ulation studies over the next decade are required to deter-
mine if a single measure of vasoreactivity in an individual
patient predicts the development of atherosclerosis or its
complications, and such studies are now in the planning
stages. In addition, the relationship between vasomotor
responses and other measures of endothelial activation
(platelet and leukocyte markers) needs to be established.
Finally, intervention studies would need to be done to
determine if intervening is prudent and effective in those
patients at increased risk because of vascular dysfunction.
Whether endothelial dysfunction in a primary prevention
population can be used as a marker for participants at higher
risk of developing atherosclerosis is yet to be proved, and
this remains a very important goal of the clinical vascular
biologist over the next two decades.
CONCLUSION
Endothelial function can now be readily measured in
humans and is a very useful research tool to assess the effect
of risk factors and their treatment on vascular function. A
growing list of therapeutic modalities have been shown to
modulate endothelial dysfunction, which has important
implications for the treatment of participants at risk of
developing atherosclerotic complications. For measurement
of endothelial function to become a clinically useful tool,
much work needs to be done. However, it is probable that
endothelial function testing will assume a prominent role in
the evaluation and treatment of patients at risk of develop-
ing coronary atherosclerosis and its sequelae.
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